Sun Pharmaceutical Industries | Business Upturn

Sun Pharma to present 14 abstracts at 2026 AAD Annual Meeting

Arunika Jain — Fri, 27 Mar 2026 15:41:33 +0000

Sun Pharmaceutical Industries Limited is set to present 14 abstracts at the 2026 American Academy of Dermatology (AAD) Annual Meeting, scheduled from March 27-31 in Denver, Colorado. This presentation underscores the company’s leadership in dermatology and immunology, highlighting its commitment to advancing treatments for conditions such as psoriasis, alopecia areata, and acne.

Ahmad Naim, MD, Senior Vice President and North American Chief Medical Officer at Sun Pharma, emphasised the importance of these presentations, stating that they reflect the company’s dedication to meaningful scientific advancements that translate into clinically significant outcomes for patients. The presentations will cover a range of topics, including clinical efficacy, safety, and real-world performance of therapies.

Key presentations include data on ILUMYA® (tildrakizumab-asmn), which showed sustained efficacy and safety in a Phase 3b study for moderate-to-severe psoriasis affecting the nails over 52 weeks. The data also demonstrated ILUMYA’s holistic disease management capabilities across diverse patient populations worldwide. ILUMYA is approved for moderate-to-severe plaque psoriasis in several countries, including the U.S., Australia, Japan, and Europe, where it is marketed as ILUMETRI®.

Additionally, pooled data from the THRIVE-AA1 and THRIVE-AA2 pivotal trials of LEQSELVI™ (deuruxolitinib) in severe alopecia areata showed significant scalp hair regrowth as early as Week 8 and Week 12, with continuous improvements over time. A survey revealed gaps in perceptions of disease burden and treatment goals, highlighting the need for better communication in patient-centered care.

The company will also present findings from an open-label, 52-week study on WINLEVI® (clascoterone cream 1%), which demonstrated significant reduction in facial sebum production and acne severity. This reinforces WINLEVI’s role in targeting the androgen-sebum pathway and its potential in multimodal acne therapies.

Sun Pharma’s booth at the AAD Annual Meeting will offer interactive experiences for clinicians, showcasing the company’s comprehensive dermatology and immunology portfolio.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Sun Pharma launches Noveltreat and Sematrinity injections in India

Arunika Jain — Sat, 21 Mar 2026 06:27:25 +0000

Sun Pharmaceutical Industries has announced the launch of its semaglutide injection under the brand names Noveltreat and Sematrinity in India. The launch includes all strengths of the medication, aimed at providing affordable treatment options for chronic weight management and type 2 diabetes mellitus.

Noveltreat is designed for chronic weight management in adults and is available in five dose strengths: 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL. It is intended to be used as an adjunct to a reduced calorie diet and increased physical activity. Sematrinity, on the other hand, is indicated for adults with insufficiently controlled type 2 diabetes mellitus and comes in two dose strengths: 2 mg/1.5 mL and 4 mg/3 mL.

The pricing strategy for these products aims to enhance affordability, with weekly therapy costs ranging from approximately ₹900 to ₹2,000 for Noveltreat and ₹750 to ₹1,300 for Sematrinity. This is significantly lower than the innovator brand.

Kirti Ganorkar, Managing Director of Sun Pharmaceutical Industries, commented on the launch, emphasising the company’s commitment to offering high-quality, affordable therapies. He highlighted the introduction of a holistic patient support programme designed to assist patients throughout their treatment journey.

Noveltreat features a prefilled pen with a concealed needle to reduce injection fear and improve safety and dosing accuracy. Sematrinity is provided in a multi-dose pen format that allows for flexible dosing, with a smooth dialer for accurate dose delivery. These pens, developed by leading global pharmaceutical device suppliers, are manufactured in Europe.

GLP-1 agonists, including semaglutide, are highly effective for treating type 2 diabetes mellitus and obesity, reducing cardiovascular and renal morbidity and mortality. With obesity and diabetes being significant health concerns in India, the introduction of these medications aims to address the urgent need for effective treatment options.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Sun Pharma and Philogen announce completion of patient enrollment for Phase III FIBROSARC trial

Matrika Shukla — Tue, 04 Feb 2025 10:52:15 +0000

Sun Pharmaceutical Industries Limited and Philogen S.p.A. have successfully completed patient enrollment for the Phase III FIBROSARC trial in Soft Tissue Sarcoma (STS), marking a significant milestone in their joint efforts to develop innovative oncology treatments.

The FIBROSARC trial, a pivotal Phase III study, aims to evaluate the efficacy of Fibromun (L19TNF) in combination with doxorubicin for the treatment of first-line locally advanced or metastatic STS. The trial, conducted across Germany, France, Italy, Spain, and Poland, has exceeded its enrollment target with 129 patients enrolled against the planned 118. Key results from this study are anticipated between March and June 2025.

Dario Neri, CEO of Philogen, expressed optimism about the progress of Fibromun’s clinical trials, stating, “We are highly encouraged by the advancements in Fibromun’s pivotal trials in both Soft Tissue Sarcoma and Glioblastoma. The completion of patient enrollment in FIBROSARC brings us one step closer to delivering an effective treatment option for STS patients. We look forward to key data readouts in the coming months.”

Sun Pharma’s Chairman and Managing Director, Dilip Shanghvi, highlighted the significance of this development in expanding the company’s oncology portfolio. “Fibromun has the potential to address high unmet medical needs in STS and other cancers. We eagerly anticipate the upcoming study results and remain committed to advancing innovative therapies,” he said.

The FIBROSARC trial is part of a broader research initiative that includes multiple ongoing clinical studies for Fibromun. The FLASH study, a Phase II trial for last-line STS treatment using Fibromun in combination with dacarbazine, has also exceeded its enrollment target with 94 patients recruited against the planned 86. Study results for FLASH are expected between April and July 2025.

In the United States, the Phase IIb FIBROSARC US study is evaluating Fibromun with doxorubicin in first-line metastatic Leiomyosarcoma patients, with 74 out of the planned 158 patients enrolled so far.

Beyond STS, Fibromun is also being investigated in Glioblastoma (GBM) through multiple clinical trials in Europe and the US. The Phase II GLIOSTAR trial in GBM has accelerated recruitment and is now expected to complete patient enrollment by Q2 2025, ahead of its original December 2025 target. Other GBM trials, including GLIOSTELLA and GLIOSUN, are progressing as planned, with data readouts expected in 2025 and 2026.

Fibromun is a proprietary biopharmaceutical product developed by Philogen, combining the L19 antibody with Tumor Necrosis Factor (TNF) to target tumor cells selectively. It is administered via intravenous infusion and is being explored for its potential to treat various cancers beyond STS and GBM, including lung, breast, colon, and prostate cancers.

Philogen and Sun Pharma have strengthened their collaboration through an exclusive global distribution, licensing, and supply agreement for Fibromun, further solidifying their joint commitment to advancing oncology treatments.

With promising study results on the horizon, the success of these clinical trials could pave the way for regulatory discussions, including a potential pre-Biologics License Application (pre-BLA) meeting with the U.S. FDA to explore accelerated approval pathways.

Sun Pharma Q1 results: Net profit declines 2% to Rs 2,022 crore; revenue up 11% YoY

Adesh Dixit — Thu, 03 Aug 2023 16:23:46 +0000

For the quarter that ended in June 2023, Sun Pharmaceutical Industries Ltd. reported a net profit of ₹2,022.54 crore, 1.86% less than the same time the previous year at ₹2,060.88 crore.

In Q1FY24, the company’s operating revenue increased by 10.95% to ₹11,940.84 crore, up from ₹10,761.76 crore in the same quarter the previous year.

YoY, earnings before interest, taxes, depreciation, and amortization (EBITDA) climbed by 27.4% to ₹3,332 crore during the quarter from ₹2,614.4 crore.

YoY, the EBITDA margin increased by 230 basis points (bps), from 25.6% to 27.9%.

Sales of Sun Pharma’s formulations in India increased 5.1% to ₹3,560.4 crore. US formulation sales reached $471 million, a 12% YoY increase. More over one-third of the company’s total consolidated sales came from sales in the US.

Taro reported Q1FY24 revenues of $159 million, up 1.4% YoY, and a net profit of roughly $10 million, down 28.9% from the same period the previous year.

“Net income was $14.9 million in the current year quarter, excluding the impact from certain one-time items, compared to the net profit of $14.1 million in Q1FY23,” the business stated.

The company’s 232 million global specialty sales increased 21% year over year. Sun Pharma said that 16.2% of Q1FY24 sales came from worldwide speciality sales.

“Every aspect of our business grew this quarter, and we are in a good position to achieve our growth targets for FY24. “Global Specialty has continued to increase as a share of our revenues, and the US has led the revenue growth in Q1,” stated Dilip Shanghvi, Managing Director of Sun Pharmaceutical Industries.

External API sales for Q1FY24 were ₹5,396 million, a 9.9% decrease over Q1 of the previous year.

The quarter’s decline in consolidated net profit was partially caused by one-time charges amounting to ₹323 crore.

Due to the devaluation of the Nigerian Naira versus the US dollar, the company had a foreign exchange loss of 122.92 crore and a one-time charge of ₹149.21 crore for the impairment of an intangible asset. Additionally, it paid ₹50.74 crore in one-time transitional costs for the anticipated move of Alchemee activities from California to New York.

The price of a share of Sun Pharma was 1.50% higher at ₹1,153.35 on the BSE at 2:30 pm.

Sun Pharma will pay $576 million to acquire Concert Pharmaceuticals

Aryan Jakhar — Thu, 19 Jan 2023 16:56:40 +0000

Sun Pharmaceutical Industries said on Thursday that it has agreed to buy US-based Concert Pharmaceuticals for USD 576 million (about Rs 4,688 crore).

Sun Pharma announced in a regulatory filing that it has inked a final agreement under which it would acquire all outstanding shares of Concert through a tender offer for an upfront payment of USD 8 per share of common stock in cash, or USD 576 million in equity value.

The first cash payment of USD 8 per share of common stock reflects a premium of about 33% above Concert’s 30-day volume weighted average price as of January 18, 2023, the final trading day previous to Thursday’s announcement.

Concert investors will also get a non-tradeable contingent value right (CVR) entitling them to an extra USD 3.50 per share of common stock in cash if deuruxolitinib meets specific net sales goals within certain time periods, according to the company.

Concert is a biotechnology business in its late stages that is pioneering the use of deuterium in medicinal chemistry.

Concert has a robust patent portfolio, including its flagship product candidate deuruxolitinib, an oral inhibitor of Janus kinases JAK1 and JAK2 in late-stage development for the treatment of Alopecia Areata, an autoimmune dermatological disorder.

Alopecia Areata is an autoimmune illness that causes the immune system to assault hair follicles, causing partial or full hair loss on the scalp and body.

“There is a significant unmet need in the Alopecia Areata space and we aim to build on Concert’s commitment to supporting the Alopecia Areata patient community. We are well-positioned to successfully bring this product to market globally,” Sun Pharma North America CEO Abhay Gandhi stated.

Sun Pharma will immediately launch a tender offer to acquire all outstanding shares of Concert common stock under the provisions of the merger agreement.

Concert investors will get a cash settlement of USD 8 per share of common stock.

Concert investors should tender their shares in the tender offer, according to the Board of Directors.

The transaction is expected to be completed in the first quarter of 2023. “Our mission at Concert has always been to translate innovative science to clinical solutions in order to meaningfully improve patients’ lives. We are proud to see our team’s accomplishment creating a valuable new drug candidate for a major, underserved disease appropriately recognized and valued by Sun Pharma as a means to expand their ongoing, international commitment to dermatology,” Concert President and CEO Roger Tung stated.

Concert reported overall sales of USD 29,000 and a net loss of USD 90.6 million for the nine-month period ending September 2022.

During the nine-month period, R&D expenses totaled USD 75.7 million. It has around USD 148.9 million in cash, cash equivalents, and assets as of September 30, 2022.

Sun Pharma has USD 1.6 billion in net cash as of September 30, 2022.